Voyager Therapeutics (VYGR) Return on Capital Employed (2015 - 2026)
Voyager Therapeutics (VYGR) posted Return on Capital Employed of 58.36% for Q1 2026, down 7.89% sequentially from 54.09% in Q4 2025, and down 2778.0% YoY from 2.18% in Q1 2025.
Voyager Therapeutics (VYGR) Return on Capital Employed (2015 - 2026) Analysis & Trends
Voyager Therapeutics has reported Return on Capital Employed for 12 years, with the latest figure at 58.36% in Q1 2026.
- Quarterly Return on Capital Employed fell 2778.0% year-over-year to 58.36% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 58.36% (down 2778.0% YoY) and the FY2025 annual result came in at 44.52%, down 1869.0% from the prior year.
- Return on Capital Employed declined to 58.36% in Q1 2026 per VYGR's latest filing, from 54.09% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 47.21% in Q4 2023 and troughed at 64.63% in Q1 2022.
- A 5-year average of 18.66% and a median of 23.15% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed sank 7630 bps in 2022, then jumped 10562 bps in 2023.
- Over 5 years, Return on Capital Employed stood at 51.7% in 2022, then surged by 191 bps to 47.21% in 2023, then sank by 149 bps to 23.15% in 2024, then slumped by 134 bps to 54.09% in 2025, then declined by 8 bps to 58.36% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 58.36%, 54.09%, and 51.99% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Voyager Therapeutics | 201.32 Mn | 84.98 Mn | - | -61.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -61.08% |
| Mar 31, 2026 | -58.36% |
| Dec 31, 2025 | -54.09% |
| Sep 30, 2025 | -51.99% |
| Jun 30, 2025 | -41.73% |
| Mar 31, 2025 | -30.58% |
| Dec 31, 2024 | -23.15% |
| Sep 30, 2024 | 2.35% |
| Jun 30, 2024 | -1.61% |
| Mar 31, 2024 | -5.05% |
| Dec 31, 2023 | 47.21% |
| Sep 30, 2023 | 17.83% |
| Jun 30, 2023 | 31.13% |
| Mar 31, 2023 | 40.98% |
| Dec 31, 2022 | -51.70% |
| Sep 30, 2022 | -18.32% |
| Jun 30, 2022 | -55.47% |
| Mar 31, 2022 | -64.63% |
| Dec 31, 2021 | -53.22% |
| Sep 30, 2021 | -60.60% |